Sildenafil Citrate Tablet
Product Images NDC 72789-405

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 72789-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789405 Label (72789405)

Packaging label for SILDENAFIL USP 50 MG tablets by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label shows a prescription-only symbol, NDC 72789-405-30, with a quantity of 30 tablets. Additional details include reorder number, lot number H24A11, and expiration date 10/2025. The label states film-coated sildenafil citrate USP equivalent to sildenafil 50 mg per tablet.*

FDA Label Image

Sildenafil-citrate-figure-1 (Sildenafil Citrate Figure 1)

A line graph showing the mean change from baseline in sitting systolic blood pressure over 24 hours in healthy volunteers. It compares two groups: sildenafil 100 mg and placebo, with time post-dose on the x-axis and systolic blood pressure change (mmHg) on the y-axis.*

FDA Label Image

Sildenafil-citrate-figure-2 (Sildenafil Citrate Figure 2)

A line graph depicting mean standing systolic blood pressure change from baseline over 8 hours postdose. Two data sets are shown: one for Doxazosin with Placebo (blue line) and one for Doxazosin with Sildenafil 25 mg (black line), illustrating blood pressure changes at multiple hourly time points.*

FDA Label Image

Sildenafil-citrate-figure-3 (Sildenafil Citrate Figure 3)

A line graph showing mean standing systolic blood pressure change from baseline over an 8-hour period postdose. Two data sets are depicted: one for Doxazosin plus Placebo and one for Doxazosin plus Sildenafil 50 mg, with time in hours on the x-axis and changes in systolic blood pressure (mmHg) on the y-axis.*

FDA Label Image

Sildenafil-citrate-figure-4 (Sildenafil Citrate Figure 4)

A line graph showing mean standing systolic blood pressure change from baseline over 8 hours after dosing. It compares two groups: one receiving Doxazosin with Sildenafil 100 mg and the other Doxazosin with placebo. The y-axis represents blood pressure change in mmHg, and the x-axis represents time after dosing in hours.*

FDA Label Image

Sildenafil-citrate-figure-5 (Sildenafil Citrate Figure 5)

A line graph depicting mean plasma concentrations of Sildenafil over time in healthy male volunteers. The x-axis represents time post dose in hours, and the y-axis shows plasma concentration in ng/mL. The curve rises sharply to a peak near 1 hour then gradually declines over 24 hours, comparing Sildenafil treatment and a commercial tablet.*

FDA Label Image

Sildenafil-citrate-figure-6 (Sildenafil Citrate Figure 6)

Two bar charts showing the effect of sildenafil citrate and placebo on maintenance of erection by baseline score. The x-axis represents baseline scores from 0 to 5, while the y-axis shows the percentage of patients at endpoint. Different bars indicate scores from 0 to 5, illustrating comparative patient outcomes between sildenafil citrate and placebo groups.*

FDA Label Image

Sildenafil-citrate-figure-7 (Sildenafil Citrate Figure 7)

A bar chart showing the percentage of patients reporting improvement across different treatment groups. Groups include Placebo, Sildenafil citrate 25 mg, Sildenafil citrate 50 mg, and Sildenafil citrate 100 mg, with improvement percentages increasing from placebo to the highest dose.*

FDA Label Image

Sildenafil-citrate-structure (Sildenafil Citrate Structure)

Chemical structure diagram of sildenafil citrate, showing its molecular arrangement consistent with the active ingredient in the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.